Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
Stammdaten
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Unternehmen & Branche
| Name | BioCardia, Inc. |
|---|---|
| Ticker | BCDA |
| CIK | 0000925741 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 6,7 Mio. USD |
| Beta | 0,55 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -8,228,000 | 3,413,000 | 895,000 | ||
| 2025-09-30 | 10-Q | -1,483,000 | 6,148,000 | 2,627,000 | ||
| 2025-06-30 | 10-Q | -2,049,000 | 2,089,000 | -1,886,000 | ||
| 2025-03-31 | 10-Q | -2,712,000 | 2,166,000 | -1,520,000 | ||
| 2024-12-31 | 10-K | -7,946,000 | 3,724,000 | 837,000 | ||
| 2024-09-30 | 10-Q | -1,737,000 | 6,267,000 | 2,753,000 | ||
| 2024-06-30 | 10-Q | -1,646,000 | 2,890,000 | -1,961,000 | ||
| 2024-03-31 | 10-Q | -2,267,000 | 2,679,000 | -2,275,000 | ||
| 2023-12-31 | 10-K | -11,571,000 | 2,987,000 | -1,603,000 | ||
| 2023-09-30 | 10-Q | -2,574,000 | 3,747,000 | -660,000 | ||
| 2023-06-30 | 10-Q | -3,424,000 | 6,389,000 | 1,635,000 | ||
| 2023-03-31 | 10-Q | -3,501,000 | 7,128,000 | 1,900,000 | ||
| 2022-12-31 | 10-K | -11,907,000 | 9,793,000 | 4,892,000 | ||
| 2022-09-30 | 10-Q | -3,057,000 | 9,179,000 | 4,097,000 | ||
| 2022-06-30 | 10-Q | -2,497,000 | 11,266,000 | 6,734,000 | ||
| 2022-03-31 | 10-Q | -3,325,000 | 12,840,000 | 7,369,000 | ||
| 2021-12-31 | 10-K | -12,623,000 | 15,718,000 | 10,375,000 | ||
| 2021-09-30 | 10-Q | -2,706,000 | 17,330,000 | 13,412,000 | ||
| 2021-06-30 | 10-Q | -3,487,000 | 20,218,000 | 15,673,000 | ||
| 2021-03-31 | 10-Q | -2,969,000 | 23,308,000 | 18,562,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 5,000 | 1.11 | 5,550.00 | +10,2% | |
| 2026-04-21 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 400 | 1.23 | 492.00 | +0,9% | |
| 2026-04-20 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 600 | 1.23 | 738.00 | +1,4% | |
| 2026-02-04 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 5,000 | 1.13 | 5,650.00 | +10,4% | |
| 2026-01-21 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 300 | 1.34 | 402.00 | +0,7% | |
| 2026-01-20 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 600 | 1.32 | 792.00 | +1,5% | |
| 2025-12-17 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 900 | 1.30 | 1,170.00 | +2,2% | |
| 2025-12-16 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 200 | 1.37 | 274.00 | +0,5% | |
| 2025-09-19 | Blank Andrew Scott | Director | Open Market Purchase | 288,000 | 1.25 | 360,000.00 | +662,5% | |
| 2025-09-19 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 48,000 | 1.25 | 60,000.00 | +110,4% | |
| 2025-09-19 | STERTZER SIMON H | Director | Open Market Purchase | 398,400 | 1.25 | 498,000.00 | +916,5% | |
| 2025-08-22 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 700 | 1.83 | 1,281.00 | +2,4% | |
| 2025-08-13 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 100 | 1.83 | 183.00 | +0,3% | |
| 2025-08-12 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 400 | 1.75 | 700.40 | +1,3% | |
| 2025-08-11 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 1,700 | 1.76 | 2,988.60 | +5,5% | |
| 2025-06-30 | Blank Andrew Scott | Director | Open Market Purchase | 72,289 | 2.08 | 149,999.68 | +276,0% | |
| 2025-06-30 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 24,096 | 2.08 | 49,999.20 | +92,0% | |
| 2025-06-30 | STERTZER SIMON H | Director | Open Market Purchase | 72,289 | 2.08 | 149,999.68 | +276,0% | |
| 2025-06-30 | McClung David | Officer, Chief Financial Officer | Open Market Purchase | 4,819 | 2.08 | 9,999.43 | +18,4% | |
| 2025-05-30 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 100 | 2.21 | 221.00 | +0,4% | |
| 2025-05-22 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 700 | 1.89 | 1,323.00 | +2,4% | |
| 2025-05-20 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 1,600 | 2.08 | 3,328.00 | +6,1% | |
| 2025-05-16 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 300 | 2.43 | 729.60 | +1,3% | |
| 2025-05-14 | Altman Peter | Director, Officer, President and CEO | Open Market Purchase | 100 | 2.99 | 298.60 | +0,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.